Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone303-625-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$95.39 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Tuesday, February, 26th. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing the consensus estimate of ($1.68) by $0.20. The biopharmaceutical company had revenue of $30.40 million for the quarter, compared to the consensus estimate of $30.46 million. Clovis Oncology had a negative net margin of 385.80% and a negative return on equity of 147.39%. The business's revenue was up 78.4% on a year-over-year basis. During the same period last year, the company posted ($1.04) earnings per share. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
What price target have analysts set for CLVS?
11 equities research analysts have issued 12 month price objectives for Clovis Oncology's stock. Their forecasts range from $21.00 to $86.00. On average, they expect Clovis Oncology's stock price to reach $42.75 in the next year. This suggests a possible upside of 105.2% from the stock's current price. View Analyst Price Targets for Clovis Oncology.
What is the consensus analysts' recommendation for Clovis Oncology?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clovis Oncology.
What are Wall Street analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. According to Zacks Investment Research, "Sales of the company’s sole marketed drug Rubraca recovered in the fourth quarter of 2018 on the back of awareness programs. However, the drug faced challenges in its adoption, which may continue going forward. Moreover, Rubraca faces strong competition from other PARP inhibitors in the market, Lynparza and Zejula. Meanwhile, several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Successful development is likely to bolster the prospect of the drug. The company is actively working on expanding the label of Rubraca as monotherapy or combination therapy in and beyond ovarian cancer. Clovis’ shares have underperformed the industry in the past six months. Clovis’ shares have outperformed the industry so far this year. Loss estimates have been stable ahead of the company’s Q1 earnings release. The company has a dismal record of earnings surprises in the recent quarters." (4/16/2019)
- 2. JPMorgan Chase & Co. analysts commented, "Clovis’ 4Q report was as expected following the top-line pre-announcement at The J.P. Morgan Healthcare Conference. Importantly, all key Rubraca clinical trials remain on track with the next material data updates likely at ESMO in September. In the meantime, we expect investors to continue to focus on the strategic value of the company, particularly in the wake of the GSK/TSRO deal. We are also increasingly asked about CLVS’s cash outlook given an accelerating operating spend and a first round of converts due in 2021 (~$284M). While these questions are likely to persist, we anticipate they will be secondary to the company’s strategic potential." (2/27/2019)
Has Clovis Oncology been receiving favorable news coverage?
News stories about CLVS stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Clovis Oncology earned a news impact score of 1.2 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Are investors shorting Clovis Oncology?
Clovis Oncology saw a decrease in short interest during the month of March. As of March 15th, there was short interest totalling 9,480,940 shares, a decrease of 11.4% from the February 28th total of 10,702,247 shares. Based on an average trading volume of 1,841,211 shares, the days-to-cover ratio is currently 5.1 days. Approximately 19.0% of the shares of the company are sold short. View Clovis Oncology's Current Options Chain.
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include United Therapeutics (UTHR), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Evotec (EVTCY), Amneal Pharmaceuticals (AMRX), ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), Emergent Biosolutions (EBS) and Biohaven Pharmaceutical (BHVN).
What other stocks do shareholders of Clovis Oncology own?
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Who are Clovis Oncology's major shareholders?
Clovis Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Congress Park Capital LLC (0.02%), Virtu Financial LLC (0.02%) and Conservest Capital Advisors Inc. (0.02%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.
Which major investors are selling Clovis Oncology stock?
CLVS stock was sold by a variety of institutional investors in the last quarter, including Conservest Capital Advisors Inc. and Congress Park Capital LLC. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, James C Blair and Lindsey Rolfe. View Insider Buying and Selling for Clovis Oncology.
Which major investors are buying Clovis Oncology stock?
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $20.83.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $1.10 billion and generates $95.39 million in revenue each year. The biopharmaceutical company earns $-368,010,000.00 in net income (profit) each year or ($7.07) on an earnings per share basis.
What is Clovis Oncology's official website?
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
